Clinical Trial News and Research

RSS

Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

The Mount Sinai Hospital is first in the United States to use the first and only FDA-approved, drug-coated balloon to open blocked arteries in the leg.

15 Oct 2014

Discovery could prolong life of people living with glioblastoma

Researchers at the University of Calgary's Hotchkiss Brain Institute and Southern Alberta Cancer Research Institute have made a discovery that could prolong the life of people living with glioblastoma – the most aggressive type of brain cancer. Samuel Weiss, PhD, Professor and Director of the HBI, and Research Assistant Professor Artee Luchman, PhD, and colleagues, published their work today in Clinical Cancer Research, which is leading researchers to start a human phase I/II clinical trial as early as Spring 2015.

14 Oct 2014

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.

14 Oct 2014

Research opens door to potential new treatments for peripheral artery disease

Researchers have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness.

14 Oct 2014

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland.

14 Oct 2014

Pharmaceutical industry withdraws from the antibiotic space

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive.

13 Oct 2014

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

Pancreatic cancer is one of the deadliest cancers. Even with aggressive treatment, the prognosis is poor, with various factors stacking the odds against successful treatment: early detection is uncommon, it tends to spread quickly and recurrence is likely. However, several newer approaches show promise in increasing the response rate to pancreatic cancer treatment.

10 Oct 2014

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.

10 Oct 2014

BHVH cardiologists implant investigational cardiac pacemaker the size of multivitamin

Cardiologists on the medical staff at Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) today implanted an investigational cardiac pacemaker the size of a multivitamin.

From Medtronic 9 Oct 2014

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

9 Oct 2014

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

9 Oct 2014

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara™ transcatheter mitral valve.

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Stiff rise in generic drug prices prompts probe by members of Congress

The prices have increased by more than 1,000 percent for some of the drugs. In other news about treatments, a study finds robotic surgery may not improve care for ovarian problems and the National Cancer Institute laments that insurers' concerns about cost are keeping some patients from proton therapy trials.

9 Oct 2014

Study: H7N9 flu vaccine combined with adjuvant is essential to promote protective immune response

A large, NIH-sponsored clinical trial of an experimental H7N9 avian influenza vaccine found an immune response that was believed to be protective in 59 percent of study participants who received two injections of the inactivated vaccine at the lowest dosage tested when mixed with an adjuvant – a component that boosts the body's immune response and enhances the effectiveness of inactivated influenza vaccines.

8 Oct 2014

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile.

8 Oct 2014

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

Ruthigen Inc., a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

8 Oct 2014

New study finds that not having close access to healthy foods can deter even motivated dieters

You're obese, at risk for diabetes and cardiovascular disease, and so motivated to improve your diet that you've enrolled in an intensive behavioral program. But if you need to travel more than a short distance to a store that offers a good selection of healthy food, your success may be limited.

8 Oct 2014

C3BS inks preferred access agreement with Mayo Clinic

Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic.

8 Oct 2014

Combination of behavioral support and medication helps people stop smoking

Numerous randomized clinical trials have shown the effectiveness of the two major forms of smoking cessation treatment - behavioral support and medication - in helping smokers quit. Researchers have now demonstrated that this approach can successfully translate to the "real world" and that a combination of the two treatments offers almost a threefold chance of success over attempts to quit without using a cessation aid.

8 Oct 2014

Clinical Trial News and Research

Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

Discovery could prolong life of people living with glioblastoma

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Research opens door to potential new treatments for peripheral artery disease

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Pharmaceutical industry withdraws from the antibiotic space

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

First study of promising Ebola vaccine commenced in West Africa

BHVH cardiologists implant investigational cardiac pacemaker the size of multivitamin

VAL-083 drug compound shows promise against non-small cell lung cancer

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Stiff rise in generic drug prices prompts probe by members of Congress

Study: H7N9 flu vaccine combined with adjuvant is essential to promote protective immune response

GenomOncology, med fusion partner to optimize treatment strategies for tumor

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

New study finds that not having close access to healthy foods can deter even motivated dieters

C3BS inks preferred access agreement with Mayo Clinic

Combination of behavioral support and medication helps people stop smoking

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery